Table 6.
Characteristics of patients on dialysis at time of allogeneic HCT from 2008-2016
| Variable | N (%) |
|---|---|
| Number of patients | 46 |
| Number of centers | 35 |
| Patient related | |
| Recipient age, median (range) | 27 (<1-70) |
| Male | 36 (78) |
| Karnofsky performance score | |
| 90-100 | 13 (28) |
| <90 | 28 (61) |
| Missing | 5 (11) |
| Race | |
| White | 28 (61) |
| Black or African American | 12 (26) |
| Asian | 3 (7) |
| Native American | 1 (2) |
| Missing | 2 (4) |
| HCT-CI | |
| 2 | 3 (7) |
| 3 | 8 (17) |
| 4 | 5 (11) |
| 5+ | 21 (46) |
| Missing | 9 (20) |
| Disease related | |
| Disease | |
| AML | 13 (28) |
| ALL | 8 (17) |
| MDS/MPN | 9 (20) |
| NHL/HL | 3 (7) |
| MM/PCD | 2 (4) |
| CML | 1 (2) |
| Non-malignant hematologic disease2 | 10 (22) |
| Transplant related | |
| Number of alloHCT | |
| 1st allo | 30 (65) |
| 2nd or greater allo | 16 (35) |
| Conditioning regimen intensity | |
| Myeloablative | 13 (28) |
| RIC | 13 (28) |
| NMA | 12 (26) |
| No conditioning | 7 (15) |
| Missing | 1 (2) |
| Graft source | |
| Bone marrow | 7 (15) |
| Peripheral blood | 30 (65) |
| Umbilical cord blood | 9 (20) |
| Donor type | |
| HLA-identical sibling | 5 (11) |
| Twin | 2 (4) |
| Other related (≥7/8 match) | 15 (33) |
| Other related (≤6/8 match) | 1 (2) |
| Well-matched unrelated (8/8) | 6 (13) |
| Partially-matched unrelated (7/8) | 4 (9) |
| Unrelated (matching indeterminable) | 3 (7) |
| Cord blood | 9 (20) |
| Missing | 1 (2) |
| GVHD prophylaxis | |
| ex-vivo T-cell depletion | 6 (13) |
| CD34 selection | 2 (4) |
| Post-CY + other(s) | 4 (9) |
| TAC +− others | 17 (37) |
| CSA +− others | 10 (22) |
| Other(s)3 | 2 (4) |
| Missing | 5 (11) |
| ATG/alemtuzumab | |
| ATG alone | 15 (33) |
| Alemtuzumab alone | 2 (4) |
| No ATG or Alemtuzumab | 24 (52) |
| Missing | 5 (11) |
| Year of transplant | |
| 2008-2011 | 15 (33) |
| 2012-2016 | 31 (67) |
| Median follow-up of survivors (range), months | 36 (13-120) |
Missing pre-TED: These cases did not have pre-TED triggered as they had a second allogeneic transplant where the pre-TED was not required a second time.
Non-malignant indications: Severe aplastic anemia: n=4; Schwachmann-Diamond: n=1, Diamond-Blackfan anemia: n=1, Omenn syndrome: n=1; Wiskott Aldrich syndrome: n=1, Leukocyte adhesion deficiency: n=1; SCID: n=1
Other GVHD prophylaxis: MMF + sirolimus: n=1; MMF +− other: n=1
Abbreviation: HCT, hematopoietic cell transplantation; CI, comorbidity index; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma, RIC, reduced-intensity conditioning; NMA, nonmyeloablative regimen; MM, multiple myeloma; PCD, plasma cell disorder; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; Flu, fludarabine; Mel, melphalan; CB, cord blood; TAC, tacrolimus; MMF, mycophenolate mofetil; MTX, methotrexate; CSA, cyclosporine; ATG, anti-thymocyte globulin